MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CODX - Co-Diagnostics Inc
$11.32
-1.88(-14.24%)4:25:32 PM 3/5/2021
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    03/2/2021CODX
    Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the development of a new point-of-care/at home PCR diagnostic testing, screening and surveillance platform designed to perform Covid-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.

    02/25/2021CODX
    Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that laboratory partner Clinical Reference Laboratory's (CRL) FDA-authorized Rapid Response COVID-19 Saliva Test, which uses Co-Diagnostics CoPrimer™ technology, is now available through Walgreens Find Care®, allowing consumers a convenient, non-invasive option for PCR-based COVID-19 testing from their own homes.

    02/24/2021CODX
    Why Co-Diagnostics Stock Is Shooting Higher Today

    Co-Diagnostics (NASDAQ: CODX), considered a coronavirus stock because of its COVID-19 testing products, was up by nearly 9% in midafternoon trading on Wednesday. The test, which has Emergency Use Authorization from the Food and Drug Administration, harnesses Co-Diagnostics' patented testing technology. In Walgreens' announcement, the company quoted Clinical Reference Laboratory CEO Robert Thompson as saying that the test "demonstrated highly accurate results with 100% sensitivity and specifici...

    02/24/2021CODX
    Clinical Reference Laboratory Makes First At-Home COVID-19 Saliva Test Available Through Walgreens Find Care®

    Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care®, a digital health platform available on the Walgreens app and Walgreens.com. Sold under CRL's HealthConfirm® brand, the COVID-19 Saliva Test is non-invasive and highly accurate, offering consumers the convenience of self-collecting the test right...

    02/24/2021CODX
    Co-Diagnostics Names New CFO and CSO

    Tuesday was a busy day in the upper managerial ranks of Co-Diagnostics (NASDAQ: CODX). The molecular diagnostics specialist appointed both a new CFO and a new chief science officer (CSO). The former is Brian Brown, who replaces current office holder Reed Benson.

    02/23/2021CODX
    Co-Diagnostics, Inc. Announces New Chief Financial Officer

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown, CPA to the position of Co-Diagnostics Chief Financial Officer ("CFO"). Dr. Jesse Montgomery, PhD has also been elevated to the role of Chief Scientific Officer ("CSO"). Reed Benson, former CFO, will remain with the Company as general counsel, and Dr. Brent Satterfield, founder and former CSO, will...

    02/17/2021CODX
    Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating

    Co-Diagnostics saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 87 to 92. Co-Diagnostics is now considered extended and out of buy range after clearing a 6.34 buy point in a first-stage cup without handle. Co-Diagnostics earns the No. 32 rank among its peers in the Medical-Biomed/Biotech industry group.